Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain

Vaccine. 2006 Jan 23;24(4):510-5. doi: 10.1016/j.vaccine.2005.07.082. Epub 2005 Aug 18.

Abstract

The potential to increase the supply of vaccine by diluting the vaccinia virus of Lister strain to face possible bioterrorism with smallpox was evaluated. Vaccinia-naïve subjects (n=97) were randomized to receive either undiluted or diluted (1:5, 1:10) vaccine, and previously vaccinated subjects (n=122) were randomized to receive either undiluted or diluted (1:10, 1:30) vaccine. Except two subjects who received 1:30 diluted vaccine, the vaccination of all subjects was successful clinically. All subjects had significant vaccinia-specific T cell and antibody responses. The diluted vaccine was not associated with decreased local or systemic reactions, lower T cell responses, or higher antibody titers when compared with undiluted vaccine. Here we show the diluted vaccine of Lister strain can be used in vaccinia-naïve subjects and previously vaccinated subjects if viral titer > or =10(8) and 10(7.5) pfu/mL after dilution, respectively. The reactogenicity of vaccinia virus may not be a dose-dependent response.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / blood
  • Dose-Response Relationship, Immunologic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neutralization Tests
  • Single-Blind Method
  • Smallpox Vaccine / administration & dosage*
  • Smallpox Vaccine / adverse effects
  • Smallpox Vaccine / immunology
  • T-Lymphocytes, Cytotoxic / physiology
  • Vaccination
  • Vaccinia virus
  • Variola virus / immunology*

Substances

  • Antibodies, Viral
  • Smallpox Vaccine